FULC supply chain intelligence for Fulcrum Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Fulcrum Therapeutics, Inc. (FULC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CAMP4-THERAPEUTICS-CORP | CAMP4-THERAPEUTICS-CORP | 92% | Fulcrum made an undisclosed upfront non-refundable, non-creditable payment to CAMP4. |
| CAMP4 | CAMP4 | 90% | We are responsible for the costs associated with the development and regulatory approvals of licensed products. |
| SANOFI | SANOFI | 90% | the Company granted Sanofi an exclusive license to commercialize losmapimod, an oral small molecule for the treatment of facioscapulohumeral muscular dystrophy, outside of the United States |
| SNYNF | Sanofi | 90% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: Reciprocal relationship from SNYN… |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | 85% | Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: the Company obtained a worldwide ex… |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | 85% | the Company obtained a worldwide exclusive license to certain intellectual property related to CAMP4's Diamond-Blackfan anemia program |
| GSK | GSK plc | 80% | Reciprocal relationship from GSK graph: Reciprocal relationship from FULC graph: GSK granted us a right of reference to certain INDs filed |
| GSK | GSK plc | 80% | GSK granted us a right of reference to certain INDs filed |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SANOFI | SANOFI | 90% | we granted Sanofi an exclusive license under certain intellectual property rights to commercialize losmapimod for the treatment of FSHD outside of the United States. |
| SNYNF | Sanofi | 90% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: Reciprocal relationship from SNYN… |
| BMY | Bristol-Myers Squibb Company | 72% | nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. As of December 31, 2024, … |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from FULC graph: nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned leve… |
| BMYMP | Bristol-Myers Squibb Co | 72% | nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. As of December 31, 2024, … |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from FULC graph: nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned le… |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | 72% | nce with the agreement, the termination became effective on , which is 120 days following the date of receipt of the notice by the Company. F- 20 million, which was allocated to the performance oblig… |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | 72% | Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: nce with the agreement, the termination became effective on , which is 120 days following the date of receipt of the … |
| SNYNF | Sanofi | 72% | nce with the agreement, the termination became effective on , which is 120 days following the date of receipt of the notice by the Company. F- 20 million, which was allocated to the performance oblig… |
| COMPANY-INCORPORATED | COMPANY-INCORPORATED | 62% | llion decrease in stock-based compensation expense; • $1.0 million of decreased facility costs primarily as a result of the expiration of our lease agreement for office space at 125 Sidney Street; an… |
| MEDICAL-CENTER-CORPORATION | MEDICAL-CENTER-CORPORATION | 62% | may be reduced in specified circumstances. The MyoKardia Collaboration Agreement continues on a country-by-country and product-by-product basis until the last to expire royalty term for a product, at… |
| PRESENTATION-FULCRUM-THERAPEUTICS-INC | PRESENTATION-FULCRUM-THERAPEUTICS-INC | 62% | n received during the reporting period requires judgment because the timing and pattern of vendor invoicing does not correspond to the progress of the studies or extent of services provided and there… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| FULC-DEBT-9680 | Warrants outstanding: 850000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| FULC-DEBT | Debt stack $5.9M | 90% | Market cache reports total debt of $5.9M. |
| FULC-DEBT-9681 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| FULC-OWNER-SUVRETTA-CAPITAL-MANAGEMENT-LLC | SUVRETTA CAPITAL MANAGEMENT, LLC | 90% | 13F overlay lists SUVRETTA CAPITAL MANAGEMENT, LLC as top holder; 168 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 |